Nuveen
ADPT icon

Nuveen’s Adaptive Biotechnologies ADPT Stock Holding History

Nuveen’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$50.8M Buy
2,366,155
+1,061,995
+81% +$16.3M 0.01% 700
2026
Q1 		$18.1M Buy
1,304,160
+517,513
+66% +$8.25M ﹤0.01% 1195
2025
Q4 		$12.8M Sell
786,647
-389,689
-33% -$6.36M ﹤0.01% 1414
2025
Q3 		$17.6M Sell
1,176,336
-66,688
-5% -$813K ﹤0.01% 1230
2025
Q2 		$14.5M Sell
1,243,024
-52,093
-4% -$473K ﹤0.01% 1294
2025
Q1 		$9.62M Buy
1,295,117
+940,275
+265% +$7.23M ﹤0.01% 1575
2024
Q4 		$2.13M Hold
354,842
– – ﹤0.01% 2361
2024
Q3 		$1.82M Hold
354,842
– – ﹤0.01% 2459
2024
Q2 		$1.28M Sell
354,842
-198,919
-36% -$631K ﹤0.01% 2603
2024
Q1 		$1.78M Sell
553,761
-79,456
-13% -$307K ﹤0.01% 2454
2023
Q4 		$3.1M Buy
633,217
+4,019
+0.6% +$18.3K ﹤0.01% 2207
2023
Q3 		$3.43M Sell
629,198
-117,385
-16% -$776K ﹤0.01% 2055
2023
Q2 		$5.01M Sell
746,583
-479,557
-39% -$3.57M ﹤0.01% 1912
2023
Q1 		$10.8M Buy
1,226,140
+419,347
+52% +$3.7M ﹤0.01% 1428
2022
Q4 		$6.16M Buy
806,793
+359,342
+80% +$2.8M ﹤0.01% 1798
2022
Q3 		$3.19M Buy
447,451
+12,861
+3% +$121K ﹤0.01% 2149
2022
Q2 		$3.52M Buy
434,590
+109,768
+34% +$965K ﹤0.01% 2152
2022
Q1 		$4.11M Buy
324,822
+22,124
+7% +$348K ﹤0.01% 2159
2021
Q4 		$8.49M Sell
302,698
-42,034
-12% -$1.29M ﹤0.01% 1797
2021
Q3 		$11.7M Sell
344,732
-53,523
-13% -$1.94M ﹤0.01% 1669
2021
Q2 		$16.3M Buy
398,255
+21,161
+6% +$823K ﹤0.01% 1530
2021
Q1 		$15.2M Sell
377,094
-62,164
-14% -$3.36M ﹤0.01% 1521
2020
Q4 		$26M Buy
439,258
+162,942
+59% +$8.4M 0.01% 1077
2020
Q3 		$13.4M Buy
276,316
+24,558
+10% +$1.03M 0.01% 1319
2020
Q2 		$12.2M Buy
251,758
+15,637
+7% +$570K 0.01% 1351
2020
Q1 		$6.56M Buy
236,121
+181,567
+333% +$5.06M ﹤0.01% 1553
2019
Q4 		$1.63M Sell
54,554
-1,534
-3% -$44.1K ﹤0.01% 2504
2019
Q3 		$1.73M Buy
56,088
+42,718
+320% +$1.74M ﹤0.01% 2464
2019
Q2 		$646K Buy
+13,370
New +$592K ﹤0.01% 2916

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Nuveen's ADPT Position: Q2 2026 in Review

Nuveen increased its Adaptive Biotechnologies (ADPT) stake by 81% in Q2 2026, buying an estimated $16.3M and bringing the position to 2,366,155 shares worth $50.8M. The position accounts for 0.01% of the portfolio, ranked #700.

Nuveen first reported a position in ADPT in Q2 2019 and has held it in 29 quarters since. 300 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

  • Nuveen held 2,366,155 shares of Adaptive Biotechnologies worth $50.8M as of Q2 2026.
  • Nuveen bought 1,061,995 Adaptive Biotechnologies shares in Q2 2026, an estimated $16.3M.
  • Adaptive Biotechnologies made up 0.01% of Nuveen's portfolio in Q2 2026, its #700 holding.
  • Nuveen first reported a position in Adaptive Biotechnologies in Q2 2019 and has held it in 29 quarters since.
  • 300 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.